These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16925575)

  • 21. The outpatient management of febrile neutropenia in cancer patients.
    Freifeld AG; Pizzo PA
    Oncology (Williston Park); 1996 Apr; 10(4):599-606, 611-2; discussion 615-6. PubMed ID: 8723296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care?
    Ammann RA; Simon A; de Bont ES
    Pediatr Blood Cancer; 2005 Sep; 45(3):244-7. PubMed ID: 15747334
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols.
    Yilmaz S; Oren H; Demircioğlu F; Irken G
    Pediatr Hematol Oncol; 2008; 25(3):195-204. PubMed ID: 18432502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outpatient management of febrile neutropenia: time to revise the present treatment strategy.
    Carstensen M; Sørensen JB
    J Support Oncol; 2008; 6(5):199-208. PubMed ID: 18551855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Febrile neutropenia: transition towards a risk-directed approach.
    Anoop P; Anjay MA
    Arch Dis Child; 2007 May; 92(5):467-8. PubMed ID: 17449532
    [No Abstract]   [Full Text] [Related]  

  • 26. Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia.
    Sung L; Alibhai SM; Ethier MC; Teuffel O; Cheng S; Fisman D; Regier DA
    J Clin Epidemiol; 2012 Jun; 65(6):627-34. PubMed ID: 22424607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer.
    Teuffel O; Amir E; Alibhai SM; Beyene J; Sung L
    Pediatrics; 2011 Feb; 127(2):e279-86. PubMed ID: 21220399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemotherapy-induced febrile neutropenia: about 200 episodes. Clinical, microbiological and therapeutic characteristics].
    Gharbi O; Ben Hadj Hassen S; Kaabia N; Limam S; Hadj Amor M; Ben Fatma L; Landolsi A; Hochlef M; Letaief A; Boukadida J; Ben Ahmed S
    Pathol Biol (Paris); 2008 May; 56(3):154-7. PubMed ID: 18178025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes.
    Zuckermann J; Moreira LB; Stoll P; Moreira LM; Kuchenbecker RS; Polanczyk CA
    Ann Hematol; 2008 Feb; 87(2):139-45. PubMed ID: 17938926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
    Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
    J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.
    Courtney DM; Aldeen AZ; Gorman SM; Handler JA; Trifilio SM; Parada JP; Yarnold PR; Bennett CL
    Oncologist; 2007 Aug; 12(8):1019-26. PubMed ID: 17766662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
    Pherwani N; Ghayad JM; Holle LM; Karpiuk EL
    Am J Health Syst Pharm; 2015 Apr; 72(8):619-31. PubMed ID: 25825185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
    Ritchie S; Palmer S; Ellis-Pegler R
    Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral antibiotics for febrile patients with neutropenia due to cancer chemotherapy.
    Lishner M
    N Engl J Med; 2000 Jan; 342(1):55-6; author reply 56-8. PubMed ID: 10627210
    [No Abstract]   [Full Text] [Related]  

  • 37. Antibiotics in 30 minutes or less for febrile neutropenic patients: a quality control measure in a new hospital.
    Corey AL; Snyder S
    J Pediatr Oncol Nurs; 2008; 25(4):208-12. PubMed ID: 18539908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?
    Talcott JA
    Oncologist; 1997; 2(6):365-373. PubMed ID: 10388071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of risk stratification to guide ambulatory management of neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.
    Worth LJ; Lingaratnam S; Taylor A; Hayward AM; Morrissey S; Cooney J; Bastick PA; Eek RW; Wei A; Thursky KA;
    Intern Med J; 2011 Jan; 41(1b):82-9. PubMed ID: 21272172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral antibiotics for febrile patients with neutropenia due to cancer chemotherapy.
    Blot E; Héron F
    N Engl J Med; 2000 Jan; 342(1):55; author reply 56-8. PubMed ID: 10627209
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.